EZ Cap™ Firefly Luciferase mRNA
EZ Cap™ Firefly Luciferase mRNA will express luciferase protein once entering cells, which is initially extracted from firefly Photinus pyralis. This enzyme catalyzes ATP-dependent D-luciferin oxidation and lead to yield chemiluminescence at about 560 nm wavelength. Firefly Luciferase is a frequently used bioluminescent reporter for gene regulation and function study. It is applicable in assays for mRNA delivery, translation efficiency, cell viability and in vivo imaging etc.
EZ Cap™ Firefly Luciferase mRNA is provided at a concentration of ~1 mg/ml with Cap1 structure. There are currently two ways to cap mRNA: One is co-transcription method, by adding Cap analogues into the transcription process. The other is enzymatic Capping. After transcription, Cap0 capping is performed by Vaccinia virus Capping Enzyme (VCE), GTP and S-adenosylmethionine (SAM). The Cap0 is then generated into the Cap1 through 2´-O-Methyltransferase and SAM. Cap1 Capping can also be performed by adding VCE, 2´-O-Methyltransferase, GTP and SAM in a one-step process. Cap 1 structure is more ideal for mammalian systems and possess higher transcription efficiency than Cap 0 structure. The addition of poly (A) tail increases the stability and lifetime of the mRNA in vitro and in vivo. Poly (A) tail also plays an important role in enhancing the efficiency of translation initiation.
- 1. Timothy H. Cheung, Alexander Fuchs, et al. "Acid-Responsive Polymer Additives Increase RNA Transfection from Lipid Nanoparticles." ADVANCED FUNCTIONAL MATERIALS Volume35, Issue2 January 9, 2025 2413220
- 2. Jingjiao Li, Jie Hu, et al. "High-throughput synthesis and optimization of ionizable lipids through A3 coupling for efficient mRNA delivery." J Nanobiotechnology. 2024 Nov 4;22(1):672. PMID: 39497197
- 3. Caitlin McMillan, Amy Druschitz, et al. "Tailoring lipid nanoparticle dimensions through manufacturing processes." RSC Pharm. 2024 Sep 23 PMID: 39323767
- 4. Kathryn A. Whitehead, et al. "Lipid nanoparticle structure and delivery route during pregnancy dictate mRNA potency, immunogenicity, and maternal and fetal outcomes." Proc Natl Acad Sci U S A. 2024 Mar 12;121(11):e2307810121. PMID: 38437545
- 5. Peng Zhang, Xiaoqing Hu, et al. "Schlafen-11 and -9 are innate immune sensors for intracellular single-stranded DNA." bioRxiv 28 February 2024
- 6. Yixuan Huang, Jiacai Wu, et al. "Quaternization drives spleen-to-lung tropism conversion for mRNA-loaded lipid-like nanoassemblies." Theranostics. 2024 Jan 1;14(2):830-842. PMID: 38169552
- 7. Yutong Hou, Sihao Lin, et al. "Alleviation of ischemia–reperfusion induced renal injury by chemically modified SOD2 mRNA delivered via lipid nanoparticles." Mol Ther Nucleic Acids. 2023 Oct 26:34:102067. PMID: 38028193
- 8. Mingzhu Gao, Maoping Tang, et al. "Modulating Plaque Inflammation via Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis." ACS Nano. 2023 Sep 26;17(18):17721-17739. PMID: 37669404
- 9. Min Li, Yixuan Huang, et al. "A PEG-lipid-free COVID-19 mRNA vaccine triggers robust immune responses in mice." Materials Horizons. PMID: 36468425
- 10. Shaoyan Gao, Xiaohe Li, et al. "PKM2 promotes pulmonary fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1 signaling." Sci Adv. 2022 Sep 23;8(38):eabo0987. PMID: 36129984
- 11. Y. Huang, M. Yang, et al. "Intracellular delivery of messenger RNA to macrophages with surfactant-derived lipid nanoparticles." Materials Today Advances.
- 12. Jiaxing Di, Zhili Du, et al. "Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size." Pharm Res. 2022 Jan;39(1):105-114. PMID: 35080707
- 13. Min Li , Sanpeng Li, et al. "Secreted Expression of mRNA-Encoded Truncated ACE2 Variants for SARS-CoV-2 via Lipid-Like Nanoassemblies." Adv Mater. 2021 Aug;33(34):e2101707. PMID: 34278613
Related Biological Data

Related Biological Data

Related Biological Data

mRNA Length | 1921 nucleotides | ||
Concentration | 1 mg/mL | ||
Buffer | 1 mM Sodium Citrate, pH 6.4 | Storage | -40°C or below |
General tips | Please dissolve it on ice and protect from RNase carefully. Avoid repeated freeze/thaw cycles as possible. Don’t vortex. Upon first use, centrifuge the tube softly and aliquot it into several single use portions. Use RNase-free reagents and materials with appropriate RNase-free technique. Don’t add to the media with serum unless mixing with a transfection reagent. | ||
Shipping Condition | Evaluation sample solution: ship with dry ice. |